OrthoTrophix Homepage

Latest News

June 12, 2019
OrthoTrophix Presents Clinical Data at European Congress of Rheumatology Demonstrating Significant Correlation between Knee Function Improvement and Cartilage Thickness Increase/Stabilization after TPX-100

June 10, 2019
Reduction in Pathological Bone Shape Change Correlates with Decreased Frequency of Knee Pain after TPX-100 Treatment

May 13, 2019
TPX-100 Delays Pathological Changes of Bone in Osteoarthritis of the Knee


OrthoTrophix is an emerging biopharmaceutical company focused on the development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone, cartilage and teeth. The primary focus of OrthoTrophix is regeneration and repair of cartilage in the knee and other joints. The company’s leading therapeutic compound, TPX-100, has demonstrated a sound safety profile as well as statistically significant and clinically meaningful improvements in function and other parameters of the knees in knee osteoarthritis subjects in a Phase 2 clinical study. In addition, the significant improvement of knee function was linked to a significant improvement in knee cartilage thickness and volume. Prior to initiation of clinical studies, TPX-100 had demonstrated ability to repair articular (hyaline) cartilage in experimental defects in the knee joints of ambulatory large animal models.